Li Chaoyang, Islam Nazrul, Gutierrez Juan Pablo, Lacey Ben, Moolenaar Ronald L, Richter Patricia
Division of Global Health Protection, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK.
BMJ Open. 2021 Nov 26;11(11):e051711. doi: 10.1136/bmjopen-2021-051711.
Previous evidence from several countries, including China, Italy, Mexico, UK and the USA, indicates that among patients with confirmed COVID-19 who were hospitalised, diabetes, obesity and hypertension might be important risk factors for severe clinical outcomes. Several preliminary systematic reviews and meta-analyses have been conducted on one or more of these non-communicable diseases, but the findings have not been definitive, and recent evidence has become available from many more populations. Thus, we aim to conduct a systematic review and meta-analysis of observational studies to assess the relationship of diabetes, obesity and hypertension with severe clinical outcomes in patients with COVID-19.
We will search 16 major databases (MEDLINE, Embase, Global Health, CAB Abstracts, PsycINFO, CINAHL, Academic Research Complete, Africa Wide Information, Scopus, PubMed Central, ProQuest Central, WHO Virtual Health Library, Homeland Security COVID-19 collection, SciFinder, Clinical Trials and Cochrane Library) for articles published between December 2019 and December 2020. We will follow the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols 2016 guidelines for the design and reporting the results. We will include observational studies that assess the associations of pre-existing diabetes, obesity and hypertension in patients with COVID-19 with risk of severe clinical outcomes such as intensive care unit admission, receiving mechanical ventilation or death. Stata V.16.1 and R-Studio V.1.4.1103 statistical software will be used for statistical analysis. Meta-analysis will be used to estimate the pooled risks and to assess potential heterogeneities in risks.
The study was reviewed for human subjects concerns by the US CDC Center for Global Health and determined to not represent human subjects research because it uses data from published studies. We plan to publish results in a peer-reviewed journal and present at national and international conferences.
CRD42021204371.
包括中国、意大利、墨西哥、英国和美国在内的多个国家此前的证据表明，在确诊感染新型冠状病毒肺炎（COVID-19）并住院的患者中，糖尿病、肥胖和高血压可能是导致严重临床后果的重要危险因素。针对这些非传染性疾病中的一种或多种，已经开展了多项初步的系统评价和荟萃分析，但结果并不明确，而且最近有更多人群的数据可用。因此，我们旨在对观察性研究进行系统评价和荟萃分析，以评估糖尿病、肥胖和高血压与COVID-19患者严重临床后果之间的关系。
我们将检索16个主要数据库（MEDLINE、Embase、全球健康数据库、CAB文摘数据库、PsycINFO、护理学与健康领域数据库、学术研究大全数据库、非洲广域信息数据库、Scopus数据库、美国国立医学图书馆的生物医学期刊数据库、ProQuest Central数据库、世界卫生组织虚拟健康图书馆、国土安全COVID-19文献集、SciFinder数据库、临床试验数据库和Cochrane图书馆），以查找2019年12月至2020年12月期间发表的文章。我们将遵循《系统评价和荟萃分析方案的首选报告项目（PRISMA）2016》指南来设计和报告结果。我们将纳入评估COVID-19患者中既往存在的糖尿病、肥胖和高血压与严重临床后果风险（如入住重症监护病房、接受机械通气或死亡）之间关联的观察性研究。将使用Stata V.16.1和R-Studio V.1.4.1103统计软件进行统计分析。荟萃分析将用于估计合并风险并评估风险的潜在异质性。
美国疾病控制与预防中心全球健康中心对该研究进行了人类受试者相关审查，确定其不构成人类受试者研究，因为它使用的是已发表研究的数据。我们计划在同行评审期刊上发表研究结果，并在国内和国际会议上展示。
PROSPERO注册号：CRD42021204371。
